Von Willebrand Factor Inhibits Mature Smooth Muscle Gene Expression through Impairment of Notch Signaling

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Meng, He ^a   Zhang, Xiaojie ^a   Lee, Soo Jung ^a   Wang, Michael M ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH RECEPTOR; NOTCH RECEPTOR 3; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; ENDOTHELIUM; ENZYME INHIBITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; LIGAND BINDING; MALE; MARKER GENE; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ANIMALS; CELLS, CULTURED; GENE EXPRESSION; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROMOTER REGIONS, GENETIC; RATS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; VON WILLEBRAND FACTOR;

EID: 84884523671     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075808     Document Type: Article

References (52)

1. Bohnen NI, Albin RL, (2011) White matter lesions in Parkinson disease. Nat Rev Neurol 7: 229-236.
2. Bohnen NI, Muller ML, Zarzhevsky N, Koeppe RA, Bogan CW, et al. (2011) Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain 134: 2358-2365.
3. de Groot JC, de Leeuw FE, Oudkerk M, van Gijn J, Hofman A, et al. (2000) Cerebral white matter lesions and cognitive function: the Rotterdam Scan Study. Ann Neurol 47: 145-151.
4. Farkas E, De Jong GI, de Vos RA, Jansen Steur EN, Luiten PG, (2000) Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol 100: 395-402.
5. Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten EC, et al. (2011) Incident lacunes influence cognitive decline: the LADIS study. Neurology 76: 1872-1878.
6. Norrving B, (2003) Long-term prognosis after lacunar infarction. Lancet Neurol 2: 238-245.
7. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, et al. (2008) Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan study. Stroke 39: 2712-2719.
8. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, et al. (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348: 1215-1222.
9. Wen HM, Mok VC, Fan YH, Lam WW, Tang WK, et al. (2004) Effect of white matter changes on cognitive impairment in patients with lacunar infarcts. Stroke 35: 1826-1830.
10. Lammie GA, (2002) Hypertensive cerebral small vessel disease and stroke. Brain Pathol 12: 358-370.
11. Lammie GA, Brannan F, Slattery J, Warlow C, (1997) Nonhypertensive cerebral small-vessel disease. An autopsy study. Stroke 28: 2222-2229.
12. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG, (2009) Cadasil. Lancet Neurol 8: 643-653.
13. Joutel A, Vahedi K, Corpechot C, Troesch A, Chabriat H, et al. (1997) Strong clustering and stereotyped nature of Notch3 mutations in CADASIL patients. Lancet 350: 1511-1515.
14. Joutel A, Andreux F, Gaulis S, Domenga V, Cecillon M, et al. (2000) The ectodomain of the Notch3 receptor accumulates within the cerebrovasculature of CADASIL patients. J Clin Invest 105: 597-605.
15. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, et al. (2001) Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 108: 161-164.
16. Alamowitch S, Plaisier E, Favrole P, Prost C, Chen Z, et al. (2009) Cerebrovascular disease related to COL4A1 mutations in HANAC syndrome. Neurology 73: 1873-1882.
17. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, et al. (2006) Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 354: 1489-1496.
18. Sibon I, Coupry I, Menegon P, Bouchet JP, Gorry P, et al. (2007) COL4A1 mutation in Axenfeld-Rieger anomaly with leukoencephalopathy and stroke. Ann Neurol 62: 177-184.
19. Gabbiani G, Kocher O, Bloom WS, Vandekerckhove J, Weber K, (1984) Actin expression in smooth muscle cells of rat aortic intimal thickening, human atheromatous plaque, and cultured rat aortic media. J Clin Invest 73: 148-152.
20. Hungerford JE, Owens GK, Argraves WS, Little CD, (1996) Development of the aortic vessel wall as defined by vascular smooth muscle and extracellular matrix markers. Dev Biol 178: 375-392.
21. Miano JM, Cserjesi P, Ligon KL, Periasamy M, Olson EN, (1994) Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis. Circ Res 75: 803-812.
22. Deaton RA, Gan Q, Owens GK, (2009) Sp1-dependent activation of KLF4 is required for PDGF-BB-induced phenotypic modulation of smooth muscle. Am J Physiol Heart Circ Physiol 296: H1027-1037.
23. Duband JL, Gimona M, Scatena M, Sartore S, Small JV, (1993) Calponin and SM 22 as differentiation markers of smooth muscle: spatiotemporal distribution during avian embryonic development. Differentiation 55: 1-11.
24. Zhang X, Meng H, Blaivas M, Rushing EJ, Moore BE, et al. (2012) Von Willebrand Factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. Transl Stroke Res 3: 138-145.
25. Noseda M, Fu Y, Niessen K, Wong F, Chang L, et al. (2006) Smooth Muscle alpha-actin is a direct target of Notch/CSL. Circ Res 98: 1468-1470.
26. Tang Y, Urs S, Boucher J, Bernaiche T, Venkatesh D, et al. (2010) Notch and transforming growth factor-beta (TGFbeta) signaling pathways cooperatively regulate vascular smooth muscle cell differentiation. J Biol Chem 285: 17556-17563.
27. Tang Y, Urs S, Liaw L, (2008) Hairy-related transcription factors inhibit Notch-induced smooth muscle alpha-actin expression by interfering with Notch intracellular domain/CBF-1 complex interaction with the CBF-1-binding site. Circ Res 102: 661-668.
28. Doi H, Iso T, Sato H, Yamazaki M, Matsui H, et al. (2006) Jagged1-selective notch signaling induces smooth muscle differentiation via a RBP-Jkappa-dependent pathway. J Biol Chem 281: 28555-28564.
29. Hicks C, Johnston SH, diSibio G, Collazo A, Vogt TF, et al. (2000) Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2. Nat Cell Biol 2: 515-520.
30. Meng H, Zhang X, Hankenson KD, Wang MM, (2009) Thrombospondin 2 potentiates notch3/jagged1 signaling. J Biol Chem 284: 7866-7874.
31. Meng H, Zhang X, Lee SJ, Strickland DK, Lawrence DA, et al. (2010) Low density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signaling. J Biol Chem 285: 23047-23055.
32. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, et al. (1999) Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 96: 111-120.
33. Meng H, Zhang X, Yu G, Lee SJ, Chen YE, et al. (2012) Biochemical characterization and cellular effects of CADASIL mutants of NOTCH3. PLoS One 7: e44964.
34. Small D, Kovalenko D, Kacer D, Liaw L, Landriscina M, et al. (2001) Soluble Jagged 1 represses the function of its transmembrane form to induce the formation of the Src-dependent chord-like phenotype. J Biol Chem 276: 32022-32030.
35. Li L, Miano JM, Mercer B, Olson EN, (1996) Expression of the SM22alpha promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells. J Cell Biol 132: 849-859.
36. Moessler H, Mericskay M, Li Z, Nagl S, Paulin D, et al. (1996) The SM 22 promoter directs tissue-specific expression in arterial but not in venous or visceral smooth muscle cells in transgenic mice. Development 122: 2415-2425.
37. Maillard I, Weng AP, Carpenter AC, Rodriguez CG, Sai H, et al. (2004) Mastermind critically regulates Notch-mediated lymphoid cell fate decisions. Blood 104: 1696-1702.
38. Dang L, Fan X, Chaudhry A, Wang M, Gaiano N, et al. (2006) Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25: 487-491.
39. Zhao N, Liu H, Lilly B, (2012) Reciprocal regulation of syndecan-2 and Notch signaling in vascular smooth muscle cells. J Biol Chem 287: 16111-16120.
40. Sadler JE, (2005) von Willebrand factor: two sides of a coin. J Thromb Haemost 3: 1702-1709.
41. Qin F, Impeduglia T, Schaffer P, Dardik H, (2003) Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. J Vasc Surg 37: 433-439.
42. Kockx MM, Wuyts FL, Buyssens N, Van Den Bossche RM, De Meyer GR, et al. (1993) Longitudinally oriented smooth muscle cells in rabbit arteries. Virchows Arch A Pathol Anat Histopathol 422: 293-299.
43. De Meyer GR, Hoylaerts MF, Kockx MM, Yamamoto H, Herman AG, et al. (1999) Intimal deposition of functional von Willebrand factor in atherogenesis. Arterioscler Thromb Vasc Biol 19: 2524-2534.
44. Morrow D, Scheller A, Birney YA, Sweeney C, Guha S, et al. (2005) Notch-mediated CBF-1/RBP-J{kappa}-dependent regulation of human vascular smooth muscle cell phenotype in vitro. Am J Physiol Cell Physiol 289: C1188-1196.
45. Proweller A, Pear WS, Parmacek MS, (2005) Notch signaling represses myocardin-induced smooth muscle cell differentiation. J Biol Chem 280: 8994-9004.
46. Sweeney C, Morrow D, Birney YA, Coyle S, Hennessy C, et al. (2004) Notch 1 and 3 receptor signaling modulates vascular smooth muscle cell growth, apoptosis, and migration via a CBF-1/RBP-Jk dependent pathway. Faseb J 18: 1421-1423.
47. Mazzucato M, Spessotto P, Masotti A, De Appollonia L, Cozzi MR, et al. (1999) Identification of domains responsible for von Willebrand factor type VI collagen interaction mediating platelet adhesion under high flow. J Biol Chem 274: 3033-3041.
48. Scheppke L, Murphy EA, Zarpellon A, Hofmann JJ, Merkulova A, et al. (2011) Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood.
49. Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, et al. (2006) High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 37: 2672-2677.
50. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, et al. (1999) Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100: 736-742.
51. Qizilbash N, Duffy S, Prentice CR, Boothby M, Warlow C, (1997) Von Willebrand factor and risk of ischemic stroke. Neurology 49: 1552-1556.
52. Wannamethee SG, Whincup PH, Lennon L, Rumley A, Lowe GD (2012) Fibrin D-Dimer, Tissue-Type Plasminogen Activator, Von Willebrand Factor, and Risk of Incident Stroke in Older Men. Stroke.